Statistics

Total Visits

Views
Weekly cabazitaxel in "unfit" metastatic castration-resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment: Preliminary results of CABASEM-SOGUG phase II trial.36

Select a period of time:

Number of views in the range

Views
Weekly cabazitaxel in "unfit" metastatic castration-resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment: Preliminary results of CABASEM-SOGUG phase II trial.17

Views

Views
November 20240
December 20240
January 20250
February 20251
March 20254
April 202512
May 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Hong Kong10
Singapore4
United States2
Spain1
 

Top cities views

Views
Hong Kong10
Council Bluffs1